Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
Key Highlights
- ➤MitoCareX completes initial computational screening stage with Boltz for drug-discovery programs
- ➤Preliminary AI predictions remain experimentally unvalidated and require further analysis
- ➤Nexentis retains control over discovery programs and any small-molecule candidates advanced
- ➤No compound identified is assured to reach preclinical or clinical development
Expert Statements
David Palach, Chief Executive Officer of Nexentis
“We believe that completing this first screening stage is an important step in translating our initiative with Boltz into research insights.”
David Palach, Chief Executive Officer of Nexentis
“We are focused on advancing proprietary discovery programs through disciplined, evidence-based decisions.”
David Palach, Chief Executive Officer of Nexentis
“These initial predictions give us a basis for planning next steps, and further validation will be essential to determining their significance.”
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation
Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC (“Boltz”), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.
Get started
Create a free account to read the full story.